Flortaucipir

CHEMBL3546271 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

263.3 g/mol

LogP

3.3

Phase

4

This PET imaging agent binds to tau protein tangles in the brain, which are a hallmark of Alzheimer's disease and other tauopathies.

Moleküler Ağırlık

263,2700 g/mol

LogP

3,30

TPSA

41,60 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Alzheimer's Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Fc1ccc(-c2ccc3c(c2)[nH]c2ccncc23)cn1

InChI

InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H

Molecular Formula

C16H10FN3

HBD / HBA

1 / 3

Döndürülebilir Bağlar

1

Ağır Atomlar

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This PET imaging agent binds to tau protein tangles in the brain, which are a hallmark of Alzheimer's disease and other tauopathies.

Yes, Flortaucipir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3546271. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71059746. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Flortaucipir PillFYI'da

Yapı

Hızlı Veriler

Formül: C16H10FN3
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.